Sauer et al., 1995 - Google Patents
In patients with orthotopic liver transplantation, serum markers of cholestasis are unreliable indicators of biliary secretionSauer et al., 1995
- Document ID
- 8495011553224638597
- Author
- Sauer P
- Stiehl A
- Otto G
- Theilmann L
- Publication year
- Publication venue
- Journal of hepatology
External Links
Snippet
Background/Aims: In patients after orthotopic liver transplantation, treatment with the novel immunosuppressant FK 506 may lead to elevated levels of alkaline phosphatase, gamma glutamyl transferase and bilirubin. Up to now it was unclear whether the excretory capacity …
- 230000028327 secretion 0 title abstract description 26
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Thomas et al. | Mechanism for the transit-induced increase in colonic deoxycholic acid formation in cholesterol cholelithiasis | |
| Musial et al. | Loss of fibrinogen receptors from the platelet surface during simulated extracorporeal circulation | |
| US20240173367A1 (en) | Compositions and methods for treating cholestatic disease | |
| Kim et al. | The role of altered bile acid metabolism in the steatorrhea of experimental blind loop. | |
| Lindblad et al. | A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease | |
| De Leon et al. | Cholesterol absorption during bile acid feeding: effect of ursodeoxycholic acid (UDCA) administration | |
| USRE41276E1 (en) | Strains of bacteria and pharmaceutical composition containing one or more of such strains and use of same for preventing and treating diseases associated with or caused by altered metabolism of bile acids | |
| Matern et al. | Pathophysiology of the enterohepatic circulation of bile acids | |
| Fromm et al. | Bile acid-induced diarrhoea | |
| Watkins et al. | Bile salt kinetics in cystic fibrosis: influence of pancreatic enzyme replacement | |
| Salemans et al. | Effect of ageing on postprandial conjugated and unconjugated serum bile acid levels in healthy subjects | |
| Sauer et al. | In patients with orthotopic liver transplantation, serum markers of cholestasis are unreliable indicators of biliary secretion | |
| MXPA97001816A (en) | Bacterials and pharmaceutical composition containing such strains and using the same to prevent and treat diseases associated with metabolism altered biliary deactives or caused by my | |
| Miettinen et al. | Origins of fecal neutral steroids in rats | |
| LaRusso et al. | Effect of litholytic bile acids on cholesterol absorption in gallstone patients | |
| Carulli et al. | Effect of the selective expansion of cholic acid pool on bile lipid composition: possible mechanism of bile acid induced biliary cholesterol desaturation | |
| Masclee et al. | Unconjugated serum bile acids as a marker of small intestinal bacterial overgrowth | |
| Rosenberg | Influence of intestinal bacteria on bile acid metabolism and fat absorption | |
| Mehta et al. | Biliary deoxycholate in patients with alcoholic cirrhosis | |
| BERNSTEIN et al. | Gamma glutamyl carboxypeptidase (conjugase), the folic acid-releasing enzyme of intestinal mucosa | |
| Pedersen et al. | Hepatic morphology and bile acid composition of bile and urine during chenodeoxycholic acid therapy for radiolucent gallstones | |
| Huhtanen | Bile acid inhibition of Clostridium botulinum | |
| Mitchell et al. | Factors affecting bile acid metabolism in cholerrheic enteropathy | |
| Peuchant et al. | Relationship between fecal neutral steroid concentrations and malignancy in colon cells | |
| Hickman et al. | Intestinal taurine and the enterohepatic circulation of taurocholic acid in the cat |